Kiniksa Pharmaceuticals (NASDAQ:KNSA) initiated dosing in its Phase 2b trial evaluating vixarelimab for the treatment of prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...
Aerpio Pharma (NASDAQ:ARPO) reported positive topline results from its Phase 2 trial evaluating razuprotafib for the treatment of elevated intraocular pressure (IOP). The study enrolled 194 patients with elevated IOP...
Prevail Therapeutics (NASDAQ:PRVL) dosed the first patient in its Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations. Frontotemporal dementia is the second...
Geron (NASDAQ:GERN) reported that its Phase 3 IMpactMF clinical trial, which is evaluating imetelstat for the treatment of refractory myelofibrosis, is open for patient screening and enrollment. The trial is designed to...
Lexicon Pharmaceuticals’ (NASDAQ:LXRX) LX9211 received FDA fast track designation for the treatment of diabetic peripheral neuropathic pain. The company is currently enrolling patients with diabetic peripheral...
Hepion Pharmaceuticals (NASDAQ:HEPA) completed patient dosing in the 75 mg cohort of its Phase 2a ‘AMBITION’ clinical trial, which is evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). In...
Savara (NASDAQ:SVRA) reported that its Phase 3 AVAIL trial evaluating AeroVanc for the treatment of cystic fibrosis failed to meet its primary endpoint. The trial enrolled 55 cystic fibrosis patients with methicillin...
TG Therapeutics (NASDAQ:TGTX) reported positive topline data from its two Phase 3 trials evaluating ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (MS)...
Pluristem Therapeutics (NASDAQ:PSTI) reported disappointing results from an interim analysis of its Phase 3 study evaluating PLX-PAD for the treatment of critical limb ischemia. Based on the interim analysis, the study...
Cytokinetics (NASDAQ:CYTK) reported positive interim results from the first cohort of its Phase 2 REDWOOD-HCM clinical trial evaluating CK-274 for the treatment of hypertrophic cardiomyopathy. In the first cohort, 21...
Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.